Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2001

View Archived Issues

MGI Pharma reviews progress during 2000

Ilex Oncology updates year-end 2000 developments; highlights plans for 2001

Year-end 2000 at The Medicines Company marked by FDA approval of Angiomax

FDA advisory committee recommends changes in Vioxx and Celebrex labeling

Preclinical data support clinical development of BN-80915, a lead homocamptothecin

FeRx initiates phase I/II trial of MTC-DOX for metastatic liver cancer

Hollow fiber model used to study in vitro cytotoxic activity of CHS-828

Cognetix awarded Phase I SBIR grant to study potential asthma treatment

Medarex and Immusol to develop fully human antibody therapeutics

BioNumerik partners with Asta Medica for oncology drug development

Effects of orally active SGLT inhibitor in animal model of type 2 diabetes

Therion Biologics and the NCI move CEA-TRICOM cancer vaccine to phase I

AltaRex initiates collaboration with University of Alberta researcher for hepatitis B treatment

New research program for CRL-5861 in cancer

Rasagiline may be preferable to selegiline for treatment of Parkinson's disease

Panacea enters collaborative agreement with MIT for anticancer antibodies

Milestone payment received by AxyS from Merck under osteoporosis research collaboration

Therapeutic agents for drug addiction, withdrawal, etc., claimed by Knoll

Vical broadens clinical development of Allovectin-7

Improved nucleoside immunomodulators in the ICN pipeline

Noval anticlotting agents reported in recent patent by Novo Nordisk

Cell Pathways presents series of apoptosis-inducing antineoplastic agents

BioTransplant-Novartis joint venture begins operations in the area of xenotransplantation

Phase III trial of MT-100 successfully concluded

BMS synthesizes and tests new heterocyclic aminopyrrolidine melatonergic agents

Spanish research institute discovers new bafilomycins in marine microbe

Preparation and use of potassium channel blockers described by NeuroSearch

Recent patent covers antiinflammatory agents from Ajinomoto

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...